- Adjusted Earnings Per Share (EPS) for Aflac in the 4th quarter was $1.25, which is less than the estimated $1.45 and also less than the $1.29 from the same period last year.
- Revenue for the quarter was $3.78 billion, a decrease of 5.8% from the previous year, and less than the estimated $4.33 billion.
- The book value per share is $38.00, slightly higher than the $36.35 from the previous year but less than the estimated $38.37.
- US net premium income remained stable at $1.4 billion, slightly less than the estimated $1.43 billion.
- US Adjusted Net Investment Income saw an increase of 9.9% from the previous year, reaching $211 million, which is more than the estimated $202.1 million.
- Benefits and claims expense increased by 3.7% from the previous year to $2.10 billion.
- Aflac’s operations in Japan saw strong medical sales in the fourth quarter due to the launch of a new medical insurance product in mid-September.
- The company currently has 3 buys, 11 holds, and 2 sells from analysts.
Aflac Inc on Smartkarma
Analysts on Smartkarma are closely following the performance of Aflac Inc, a leading insurance company. According to Baptista Research, the company has reported impressive numbers in the previous quarter, with a 12.4% increase in sales in Japan. This growth is mainly attributed to a rise in cancer insurance sales, thanks to partnerships with Japan Post Company and Japan Post Insurance. As Aflac continues to strengthen its market position, it remains committed to prudent liquidity and capital management.
Baptista Research also reports that Aflac managed to surpass analyst expectations in terms of revenue and earnings. The company’s strategic initiatives in the United States and Japan have yielded strong results, positioning Aflac for future growth. In Japan, the launch of new products and refreshed policies, such as WINGS cancer insurance, has contributed to significant sales growth, particularly in the cancer insurance segment. This bodes well for the company’s future prospects and has garnered a positive sentiment from analysts on Smartkarma.
A look at Aflac Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Aflac Inc, a general business holding company, is expected to have a positive long-term outlook according to the Smartkarma Smart Scores. With a score of 3 for value, the company is considered to be fairly valued in the market. Additionally, Aflac scores a 2 for dividend, indicating a moderate level of dividend payments to shareholders. This could be attractive for investors looking for steady income.
In terms of growth, Aflac scores a 3, suggesting a stable growth outlook for the company. This is supported by its diverse range of products, including accident/disability plans, cancer expense plans, and short-term disability plans. Aflac also scores a 3 for resilience, indicating its ability to weather economic downturns and maintain its operations. And with a score of 4 for momentum, Aflac is showing positive market momentum and could potentially continue to see growth in the future.
Overall, Aflac Inc is a strong company with a solid track record of providing supplemental insurance to individuals in the United States and Japan. Its diverse product offerings and positive outlook on key factors such as value, dividend, growth, resilience, and momentum make it a promising investment option for those looking for long-term stability and potential growth in the insurance industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
